Novo Nordisk
Biotech

Novo drops oncology ambitions, early-stage MASH prospects

The Danish pharma is winding down a range of early-stage programs for liver disease, oncology and stem cells.
James Waldron Nov 5, 2025 7:21am
Syneos HealthOvarian Cancer Trials 16x9v2png

Protocol-Ready Doesn’t Mean Trial-Ready in Ovarian Cancer Clinical Trials

Nov 3, 2025 8:00am
Shield soldier knight armour sword

Braveheart, with Biogen CEO on board, rallies $185M series A

Nov 5, 2025 7:51am
How do you get pharmaceutical treatments where theyre needed most

How to get pharmaceutical treatments where they’re needed most.

Oct 6, 2025 8:00am
Graphic image of a red thumbs down against a blue background

FDA rejects Biohaven approval request, triggering cost cutting

Nov 5, 2025 4:02am
Group white water rafting on river rapids

Charles River to cuts costs, shift direction as revenue slides

Nov 5, 2025 12:54pm
More News

Lilly inks $345M antibody pact with XtalPi subsidiary

Nov 5, 2025 7:00am

Lilly pulls out of CNS portion of $960M collab with Rigel

Nov 5, 2025 7:00am

Fierce Biotech Fundraising Tracker: Braveheart, Azalea & more

Nov 5, 2025 6:33am

Amgen halts gastric cancer trial after subpar efficacy analysis

Nov 5, 2025 4:35am